Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 4/20 | 0.50 |
| ▸ | MC5R | P33032 | 3/20 | 0.50 |
| ▸ | MC3R | P41968 | 3/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791119 | 1.00 | MC4R (0.50) | MC4RMC5RMC3RPIN1ALPI | |
| SCHEMBL25404698 | 0.89 | PTGES (0.47) | MC4RMC5RMC3RPIN1SLC7A5 | |
| SCHEMBL8155355 | 0.86 | PIN1 (0.45) | MC4RMC5RMC3RPIN1ALDH1A1 | |
| SCHEMBL8732931 | 0.86 | PIN1 (0.45) | MC4RMC5RMC3RPIN1ALDH1A1 | |
| SCHEMBL8123534 | 0.86 | MEN1 (0.43) | MC4RMC5RMC3RPIN1ALDH1A1 | |
| SCHEMBL6298201 | 0.85 | PIN1 (0.47) | PIN1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL27565891 | 0.85 | PIN1 (0.47) | PIN1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL1883119 | 0.84 | PIN1 (0.51) | PIN1ALDH1A1LMNAPOLBHSD17B10 | |
| Hydrochloric Acid SCHEMBL9833733 | 0.82 | MC4R (0.63) | MC4RMC5RMC3RPKMALDH1A1 | |
| SCHEMBL15173708 | 0.82 | PIN1 (0.54) | PIN1ALDH1A1LMNAPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| US-6090813-A | Use of oxido-squalene cyclase inhibitors to lower blood cholesterol | ZENECA LIMITED (GB) | 2000-07-18 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | MC4R 2123/4885MC5R 1144/4885MC3R 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.